🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› mCRPC (Metastatic Castration-resistant Prostate Cancer)
Clinical trial register · United States · industry-sponsored

mCRPC (Metastatic Castration-resistant Prostate Cancer) Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9109 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:27 UTC
9109
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 4 Massachusetts 3 Michigan 3 Florida 3 South Carolina 2
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Flare Therapeutics Inc.1 Celcuity Inc1 Pathos AI, Inc.1 Acerand Therapeutics (Hong Kong) Limited1 Aktis Oncology, Inc.1
State
California4 Massachusetts3 Michigan3 Florida3 South Carolina2
All 19 states
Target enrolment
to
5 of 9109 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas, Virginia
2026-07-01
Recruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
Aktis Oncology, Inc.
Phase 1
138
California, Florida, Kansas, Massachusetts, Michigan, Nebraska
2026-06-17
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited
Phase 1
88
California, Florida, Maryland, Massachusetts, Minnesota, Nebraska, South Carolina, Washington
2025-05-12
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
Celcuity Inc
Phase 1/2
54
Michigan
2024-01-01
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/mcrpc-metastatic-castration-resistant-prostate-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.